NorthSea Therapeutics

What NorthSea Therapeutics does

NorthSea Therapeutics B.V. is a Dutch clinical-stage biotechnology company, headquartered in Amsterdam and founded in 2017, developing Structurally Engineered Fatty Acids (SEFAs) — a proprietary class of synthetic fatty acid analogs designed to target fatty acid receptors and signaling pathways underlying metabolic, cholestatic, and fibrotic diseases. The company's pipeline comprises three orally administered, liver-targeted clinical-stage candidates: Icosabutate, an FFAR1/FFAR4 agonist advancing into a registrational Phase 3 program for metabolic dysfunction-associated steatohepatitis (MASH); Orziloben (SEFA-6179), a medium chain fatty acid analog in Phase 2 development for intestinal failure-associated liver disease (IFALD) and recipient of FDA and EMA Orphan Drug Designations as well as FDA Rare Pediatric Disease Designation; and SEFA-1024, a semi-synthetic EPA derivative in Phase 2a for severe hypertriglyceridemia (sHTG). The SEFA platform is engineered to confer oral bioavailability, portal-vein liver targeting, and resistance to rapid metabolism, enabling multi-modal mechanisms spanning inflammatory, cholestatic, and fibrotic pathways in indications with significant unmet medical need.

The company serves patients with rare liver diseases and metabolic disorders. IFALD is a rare, chronic life-threatening condition with no approved pharmacologic treatment and an estimated US patient population of ~40,000 adults and ~3,600 pediatric patients; sHTG affects approximately 3.5 million Americans with up to 50% of patients inadequately controlled by existing therapies; and MASH affects an estimated 14% of the middle-aged US population. The company reports no named commercial customers and addresses its patient populations exclusively through clinical development rather than direct distribution.

NorthSea is pre-revenue and finances operations through venture capital, having raised approximately $149M across three rounds — a Series A of ~$29M (2017, BGV/Forbion), a Series B of ~$40M (2020, led by venBio Partners), and a Series C of $80M (December 2021, co-led by Ysios Capital and Forbion Growth), with participation from Novo Seeds, Sofinnova, New Science Ventures, and Hercules Capital. The company operates with 11–50 employees and is led by CEO Rob de Ree, CSO David A. Fraser, CFO Mats Blom, and CMO (Sophie Jeannin per firmographic data / Patrick Round per funding data), with Sander Slootweg as Board Chair and Pamela Vig, Ph.D. (ex-Mirum Pharmaceuticals co-founder) as an independent Board member since March 2026. Future revenue is anticipated from commercialization of approved drugs via standard pharmaceutical distribution channels, contingent on regulatory approval.

Name

NorthSea Therapeutics

Legal name

NorthSea Therapeutics B.V.

Website

https://northseatherapeutics.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

NorthSea Therapeutics is a Dutch clinical-stage biotech developing proprietary structurally engineered fatty acids (SEFAs) — oral, liver-targeted therapeutics for MASH, IFALD, and severe hypertriglyceridemia, addressing unmet needs in rare liver and metabolic diseases.

Ownership category

akta.pro rank

Product category

Liver Disease Biopharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI)

akta.pro secondary industry

Endocrinology & Metabolic Specialty Pharmaceuticals (HLAIACAD)

Keywords

• Lipid therapeutics
• Metabolic liver disease
• Fatty acid therapeutics
• Rare disease drugs
• Hepatology drug development

Headquarters

HQ city

Naarden

HQ country

Netherlands

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Drug Development and Commercialization: Pre-revenue clinical stage biotech company developing novel therapeutics. Revenue will be generated through commercialization of approved drugs upon successful completion of clinical trials and regulatory approvals.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

NorthSea Therapeutics is a clinical-stage biotechnology company that develops orally administered, structurally engineered fatty acid (SEFA) drug candidates for metabolic, cholestatic, and fibrotic liver diseases. Its current portfolio comprises three clinical-stage assets—Icosabutate (Phase 3, MASH), Orziloben (Phase 2, IFALD), and SEFA-1024 (Phase 2a, severe hypertriglyceridemia)—designed to reach the liver via the portal vein and resist rapid metabolism, modulating fatty acid receptors and signaling pathways.

Product overview

NorthSea Therapeutics B.V. is a late-stage clinical biotechnology company developing structurally engineered fatty acids (SEFAs) as novel drugs for metabolic, cholestatic, and fibrotic diseases. The company's product portfolio consists of three clinical-stage drug candidates: Icosabutate (Phase 3, for MASH), Orziloben/SEFA-6179 (Phase 2, for IFALD), and SEFA-1024 (Phase 2a, for severe hypertriglyceridemia). These structurally engineered fatty acids are designed to target key disease pathways and fatty acid receptors, offering potential first-in-class treatments with multi-modal mechanisms of action.

Differentiator

Problem solved

Functional benefit

Products and services

• Icosabutate Oral, once-daily, liver-targeted free fatty acid receptor (FFAR) 1 and 4 agonist designed to target the liver via the portal vein and resist metabolism as an energy source; in clinical development for metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis improvement demonstrated independently of changes in liver fat or body weight.
• Orziloben (SEFA-6179 / NST-6179) Oral, once-daily, highly bioavailable, fully synthetic medium chain fatty acid (MCFA) analog that is passively absorbed from the gut and directly targets the liver via the portal vein while resisting rapid metabolism; in clinical development for intestinal failure-associated liver disease (IFALD), a condition with no approved pharmacologic treatment options.
• SEFA-1024 Oral, gut/liver targeted, semi-synthetic eicosapentaenoic acid (EPA) derivative in development for severe hypertriglyceridemia (sHTG); targets the gut-liver axis and multiple fatty acid sensitive receptors while acting as an FXR antagonist.

Quantifiable outcome

• Phase 2b ICONA study: 49.2% of 600mg treated MASH patients achieved ≥1-stage improvement in fibrosis (p=0.02 vs placebo) as assessed by qFibrosis
• +3 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

Market position

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/northseatherapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds4 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NorthSea Therapeutics